AbbVie: Renal Insufficiency trials

The registry lists 17 Renal Insufficiency studies with AbbVie as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 8Phase 2 1Phase 3 2Phase 4 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney DiseaseCompletedNCT02207088Phase 3Results posted
• Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid GlandsCompletedNCT01273597Results posted
• Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical PracticeCompletedNCT01083849Results posted
• Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek ExperienceCompletedNCT01083186Results posted
• Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy FemalesTerminatedNCT00787618Phase 1/2Results posted
• The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4CompletedNCT00497146Phase 3Results posted
• Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) PatientsCompletedNCT00224055Phase 4Results posted
• Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic AgentsCompletedNCT00224042Phase 4Results posted
• A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal FunctionCompletedNCT05940402Phase 1
• To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal FunctionCompletedNCT05404542Phase 1
• Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal FunctionCompletedNCT04810598Phase 1
• Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female SubjectsCompletedNCT02634437Phase 1
• Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal FunctionCompletedNCT02442258Phase 1
• Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal FunctionCompletedNCT01923857Phase 1
• Comparison Between Effects of Two Iron Preparations on Protein in the UrineCompletedNCT00534144Phase 1
• Effect of Two Iron Preparations on Protein in the UrineCompletedNCT00354692Phase 4
• DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)CompletedNCT00224081Phase 4